phrykt

Silver Point Capital L.P.: insider trades and track record

As of Aug 13, 2026, Silver Point Capital L.P. filed 6 open-market purchases worth $78M and 6 sales worth $407M in 4 companies since Dec 11, 2023, from Form 4 filings. At the latest insider trade price in each stock, 4 of 5 purchases are worth more than the price paid (median change +1%).

Latest filing Aug 13, 2026. From Form 4 filings. Data only, not investment advice.

At a glance

Bought, 3 years$78M6 purchases
Sold, 3 years$407M6 sales
Result on shares bought, then sold–Nothing sold yet
Change on shares still held-$455K-1% vs $69.2M paid, at latest insider price
Companies4Where they are an insider

Track record by company

One row per company: what they paid, what they got for shares sold later, and how the shares they still hold compare with the latest insider trade price.

StockRoleBoughtAvg price paidResult on shares soldShares still heldLatest priceChange on held shares
Keenova Therapeutics plc10% owner$69.2M$91.60–755,500$91.00 Nov 10, 2026-1%
THS10% owner$8.8M$24.54–357,917no recent trade–

2.47M shares sold were not bought in the open market in our data (stock awards, options or purchases before Nov 17, 2023), so they have no return.

Every purchase and the latest price

Each open-market purchase, next to the most recent price any insider paid or received for the same stock.

DateStockSharesPrice paidValueLatest priceChange
May 20, 2026Keenova Therapeutics plc210,000$90.50$19M$91.00 Nov 10, 2026+1%
May 19, 2026Keenova Therapeutics plc187,500$90.50$17M$91.00 Nov 10, 2026+1%
Feb 10, 2026THS357,917$24.54$8.8Mno later trade–
Nov 19, 2025Keenova Therapeutics plc42,000$88.88$3.7M$91.00 Nov 10, 2026+2%
Nov 17, 2025Keenova Therapeutics plc26,000$88.88$2.3M$91.00 Nov 10, 2026+2%
Nov 10, 2025Keenova Therapeutics plc290,000$93.75$27.2M$91.00 Nov 10, 2026-3%
How this track record is worked out
  • Only open-market purchases and sales (Form 4 codes P and S) from the last 3 years. Shares received as pay, from options or before that window are not purchases, so they never count toward a return.
  • Result on shares sold matches each sale with this insider's own earlier purchases in the same company, oldest first, using the prices in their filings.
  • Latest price is the price of the most recent open-market trade any insider filed in that company, with its date. It is not a live stock quote, and it is not shown when it is more than 120 days old.
  • Prices are adjusted for stock splits, found when the company's shares outstanding (from its 10-Q and 10-K covers) and the trade prices move by the same split ratio.
  • A trade reported jointly by several owners (a fund, its manager, its partners) is shown once, under the first owner named in the filing.
  • Past results say nothing about future trades. This is a record of filings, not a recommendation.

All open-market trades

Purchases and sales by month for the last 3 years. Click a month to see only its trades.

$172M$172MDec 23Jun 24Dec 24Jun 25Dec 25Jun 26
Purchases Sales Click a bar to show only that month below
DateStockInsiderRoleTypeSharesPriceValueFiling
Aug 11, 2026QVCGSilver Point Capital L.P. +210% ownerSale50,000$17.50$875KForm 4
May 20, 2026Keenova Therapeutics plcSilver Point Capital L.P. +210% ownerPurchase210,000$90.50$19MForm 4
May 19, 2026Keenova Therapeutics plcSilver Point Capital L.P. +210% ownerPurchase187,500$90.50$17MForm 4
Mar 3, 2026GPORSilver Point Capital L.P. +2DirectorSale84,416$204.22$17.2MForm 4
Mar 2, 2026GPORSilver Point Capital L.P. +2DirectorSale759,740$204.22$155MForm 4
Feb 10, 2026THSSilver Point Capital L.P. +210% ownerPurchase357,917$24.54$8.8MForm 4
Nov 19, 2025Keenova Therapeutics plcSilver Point Capital L.P. +210% ownerPurchase42,000$88.88$3.7MForm 4
Nov 17, 2025Keenova Therapeutics plcSilver Point Capital L.P. +210% ownerPurchase26,000$88.88$2.3MForm 4
Nov 10, 2025Keenova Therapeutics plcSilver Point Capital L.P. +210% ownerPurchase290,000$93.75$27.2MForm 4
Dec 19, 2024GPORSilver Point Capital L.P. +2DirectorSale529,410$162.81$86.2MForm 4
Mar 19, 2024GPORSilver Point Capital L.P. +2DirectorSale500,000$154.29$77.1MForm 4
Dec 11, 2023GPORSilver Point Capital L.P. +2DirectorSale550,000$128.21$70.5MForm 4

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.